Health Tech Challengers SUPERFINALS

[Music] ladies and gentlemen welcome back and we are starting uh health tech challenges super finals for those uh of of you who don't know it is uh the most exciting industry startup competition of the year identifying the world's top digital health care and health tech innovators this year we have received over 400 applications but only 60 startups uh made to the top to compete for an equity-free money price and the attention of key global investors the day before yesterday the finalists pitched their companies live to remarkable members of the jury and uh after that decision making our judges uh have picked six game-changing challenges so first of all let's give it up uh for our incredible jury marco amer head of ecosystems scouting and programs at 5 hd digital hub sander ruttenberg global digital health solutions he had for immunology hepatology and dermatology at novartis jennifer pune data policy strategy leads personalized healthcare at hoffman laroche uh omur hostage digital innovation lead at gsk mina handlin leading specialist at citra ratim abdul hussein clinical fellow ai and robotics at health education england cela azos global director digital health at novartis troopin moddy director of digital health innovation strategy at microsoft uh tom denvert chief digital officer of population health partners jake priegoff the director of research at gangels uh kasparov selectnavicus head of medical affairs at kilohealth laura modiano business development healthcare and life science startups er emir at amazon web services dadas long guide is co-founder and cfo of uh kilo health and uh aymantas mcshis cpo at uh kilo health so thank you judges for joining us today and i uh really think that our super final will be interesting uh uh for you and for our viewers and i hope that you are ready for the first uh pitch of our super final so please meet uh alex rajgood from predictive the winner in so ladies and gentlemen uh sorry for technical inconvenience uh yeah we had some uh technical issues we hope that everything is solved i'm happy that carlos rodriguez is with us again so once again carlos rodriguez from uh uh cogni fate uh winner in the mental health category uh so let's try uh to do everything from the beginning carlos now okay five minutes for your presentation and then five minutes for q a okay perfect let's hope this time is gonna go fine so once again i'm carlos rodriguez i'm the ceo of cognitive and it's a honor to have the opportunity to teach you about this amazing technology that we have created so now what happened okay our business is to maintain brain health and treat neurological disorders this is a big challenge and we want the population continue to grow older quickly in this in this world our solution our solution is an effective treatment for affected cognitive function with no size effect we have created probably the most complete digital cognitive assessment intervention that exists today cognifit assess 23 fundamental cognitive skills the one that you see on the screen detecting strengths and weaknesses and generating unique training sessions to improve each one of those skills we call it the individualized training system technology a technology that automatically analyzes hundreds of thousands of possible gain combinations to deliver the most efficient training outcomes it's kind of magic to see to watch how the users receive different experience every time they use the system what we do is that we challenge the user's brain neuroplasticity to reconnect neural pathways so that the people can regain cognitive disabilities and we do this with a variety of carefully designed cognitive tasks so i was saying before users just play cool games but actually they are performing performing a cognitive therapy and one that thanks to software is adjusting to the revolving needs in real time we create games because spacious engagement is one of the key elements for the treatment to work the trick is balancing between what the patient must do in order to improve and how to keep them engaged in the doing the treatment long enough from the houses so obviously we track measure and report many things about the progress and the health brain health of the users i've been working more than 10 years on building this system this is today a scalable cloud-based platform designed to capture and process billions of data points in real time that becomes more effective with every new user than sign up and we sign up one new user every 30 seconds now and with every new games that we add to the platform and we keep adding games one per month we have already completed the first three layers of the system data norms artificial intelligence models and service tools and now we are moving into the next generation of products digital therapeutics for brain conditions such as depression stroke insomnia we'll talk more in a few moments so how do we make money out of all these we work on six value generation strategies the obvious one direct to consumers to our apps our websites and then we work in 6v6 business to business different verticals five care delivery education research pharmaceuticals and insurance company what is our progress so far so far we have invested more than 30 million dollars in building this platform through the years the technology is in the market already about 4 million people in 19 languages has experienced cognifit so far so we are generating some revenues in the b2b segment and that's very important without any marketing spending because we have been solely focused on validating the technology we generate about one million dollars a year without a third personal one and all organic growth so in the b2b verticals that we have seen before we generate value through different elements clinical data generation product validation scientific publications and of course we integrate with some big partnership that space money as well but there is more as i said before we have a pipeline of digital therapeutics products to treat cognitive decline associated to brain conditions that is coming very soon all this is done and managed to a very small team of about 30 people my thin very efficient one i'm always surrounded by scientists that push our technology for the next frontier all the time and some business people helping me well not to make too many mistakes at least in the same day the company is profitable already moving into a global commercial expansion with the current portfolio products that i mentioned before and we are about to become the digital pharma with the biggest pipeline of digital therapeutical products for treating cognitive symptoms in the world i think so what i'm doing now is fundraising 50 million dollars to bring the company to the next level because after all these years of work i think we are more than ready to succeed so if you are interested in joining me in this amazing journey we are here to help millions of people to have a better life thank you carlos rodriguez thank you so much uh once again we apologize to the jury to our audience for the technical issues with our technical uh team they made every effort to eliminate that barrier and we hope that now everything's gonna be okay so now it is time for the jury questions uh to carlos who would like to start okay i put my hand up so if i could start uh great to see carlos that i think it referenced 22 academic studies that's right yeah were any of those randomized so were there a randomized control trial within those 22 yeah several of them most of them actually i can say so there is different levels of quality in the studies because we have many studies through the years some in more in the academical side originally like even 10 years ago some others more on the validation side so there is a i will say at least six or seven studies with random minds control a double blind legs in the stadium those are the ones actually that we are going to be using for the for the fda uh approvals for different claims that we are looking for clearance yeah that's in the process we are right now and and you need to know as well that we have like about 200 studies running in parallel as we speak most of them are small studies but still there is about 60 that are significantly important studies well designed as well with enough methodology to to be a proper study thank you we still got three minutes more questions to carlos so i may follow about the studies you mentioned uh several diagnosis and several different brain functions like uh in which of those maybe functions or diagnosis are you doing the best and the worst according to the outcomes of your studies so we have we see the way cognitive works and what we are trying to to get clearances like we treat cognitive symptoms associated to brain conditions so let's say for example where we have uh good studies proving that we make a significant improvement is for example insomnia uh in depression uh well basically where we what we can prove is that a population that has insomnia suffer for several cognitive symptoms decline affected in a number of cognitive abilities that we measure so we have a good tool measuring as a user system three coherent abilities and six or seven are affected by different fire insomnia for example so what happened is that our studies are proven that you significantly improve the cognitive abilities that has been affected by the symptom uh to your question the most advanced that we have are for insomnia depression a stroke and we are looking to copy it as well two minutes left okay i think i i i'm on the next on the line thank you carlos very impressive presentation and and you are really in the heart of the thing where the digital field is going uh my question is now that uh now you are in the u.s market so what kind of plans you have for for scaling your your solution in other markets for instance in europe and how well you are aware of their their digital health assessments and and and this regulatory pathways in in europe for instance yeah so basically uh we have been operating through all the years kind of in the wellness space because they didn't it's not regulated so we can sell and the money we are making like a a two million dollars that we are making in revenues come from the wellness space that has some big leverage for improving on or putting marketing on the wellness side so what we are doing now is getting approval fda approval for the american market and then moving with the with the same products and the same claims into the european agencies to get approval in europe for physical therapeutics i know that germany is well advanced uh but this is part of my roadmap so that's why i'm basically raising the money in order to boost two elements one element is marketing for the wellness market that we already have a mature technology and commercialized and completed the the regulatory approvals both in the u.s and europe in order to start selling the digital therapeutical products always treating cognitive symptoms and starting in the us following up very good in europe as our platform is multi-language are already ready for for going in in the other countries we have already like more than one million users in europe thank you jury for your questions time's up many thanks to carlos rodriguez and now we ask uh jury to cast your votes on the voting platform and i hope that now we will succeed to connect again to alex uh rosh good from uh predictive and uh i i i hope that we're gonna have his uh pitch again on our uh on our broadcast and i hope that there will be no more uh you know technical issues so alex we're trying to reach you i hope you can hear us i would like to remind the you that uh alex rosh good from predictive is the winner in the telemedicine and personalized care category again we will ask him for his presentation for five minutes and then we're gonna have five minutes for q a alex i apologize for the first time uh let's keep that as the rehearsal okay but we loved your enthusiasm and um i personally thought that uh it would be unfair if we leave you as that without questions but i think it's gonna be much even better because now we're gonna have one more time your presentation and then and then we're gonna have your questions uh uh from from the jury but uh our technicians say that you uh still uh didn't share your screen so please share your screen and uh we can uh start over okay fine everything is fine now it is time for you okay very good thank you i i hope that my internet connection will be better and that problems are solved uh on both sides so um so i'm alex rocheguard i'm the ceo and co-founder of predictive uh the first dna based digital twin to predict and prevent diseases so there are 400 million people in the world that suffer from a rare disease that's one out of 15. at the same time there are 17 million people that 17 million cancers that are diagnosed every year in the world and what we what science knows today is that over 10 percent of serious diseases have a genetic component and could have been prevented this is why we build predictive minority report for health so in this movie tom cruise as a police officer uses a solution to predict crimes before they happen so he can prevent them what we are offering to clinicians physicians genetic counselors is the same solution for health to help them predict this disease before the symptoms appear so they can prevent them and to do that we we introduced the first dna based digital tween so we make a digital version of you based on your 20 000 genes that enables us to assess the level of risk on 22 500 diseases to simulate your body reaction to over 750 drugs and we made a solution that is easy to use so not only for the phys physician for the genetic counselor or genomics experts but also for the patients and general practice doctors we have that solution that is also searchable and real time which means that you can google your dna you can search by disease by genes by drugs so that enables uh to guide the diagnosis or to identify the risk of diseases and because this is real time and searchable it also evolves over time because we update our data on a very regular basis so we always have the latest findings in research so the we have the most comprehensive solution on the market today with a thousand times smaller diseases than any other solution and the reason why we have that is because today other solutions every time they want to assess the level of risk on one disease they hire a team of researchers to look into all the papers into a public databases and to identify the gene variants the level of evidence the clinical significance and many other criterias what we have done is that we have automated that entire process so we look at 100 percent of diseases known to have genetic components we look at 100 of chin variants we match that in our genomics pipeline and [Music] based on the level of evidence based on the clinical significance and many other criterias we are able to define the genetic decrease the inborn disease risk but we didn't stop there we added the our ai engine but um to bring on also health data so it could be your ecg from your watch could be your uh your weight from uh from a scale and we add also the medical history and based on that we're able to provide you real-time information and we wanted it to make make it easy today when you want a clinical-grade genetic test you need to have blood samples we developed a proprietary protocol based on nails to extract the dna which make it easy so from the comfort of your home you can get you can get your samples and send them to us so how do we go on the market we partner with healthcare professionals with retailers that provide our solution recommend prescribe our solution to their patients we then collect the dna bill extract sequence and analyze the dna and to build the digital twin and then we have that genetic counseling session that is very important part of the package which is there to explain uh explain the results but also um set up a preventive plan we have signed a large number of partnerships and uh in the past uh in the past few months with dna visit hill well 24 somos and many others to distribute our solution to prescribe our solution to use our solution so we have this amazing team with uh sadrung and si jung identical twin brothers both teaching genomics at johns hopkins um myself a syrian entrepreneur with two successful exits and partner former partner at kpmg milani chief medical officer and md physician and johns hopkins trained by informatician and alexander our cto is a full stack software engineer with an extensive startup experience so what we're doing at predictive is not only improving the healthcare system we're trying to revolutionize the healthcare system by going from a reactive medicine to a proactive medicine so we're bringing the future of medicine today and we raised for that in june one first round of 1.2 million dollars led by team draper plug-and-play ventures and over 1500 individual investors during our equity crowdfunding campaign we have signed contracts for covering over 200 hospitals and clinics 3 300 clinicians and we already have over 250 orders and pre-orders so we're very excited by that and by the way i didn't mention it the first time but you can test your dna today on www.predictive.gear thank you thank you alex now it is time for the questions from our distinguished yuri who will start first maybe i could ask the first question if that's all right because ask the first question well done for your very ambitious uh approach alex and your pitch and i guess the question which is really burning is how do you know it works what evidence have you got what randomized control trial or observational research have you conducted so we have really thanks a lot for your question that's a very important one and you can imagine that all physicians genetic counselors or hospitals are asking us the same question um there are really two parts in our solution the first part is really on the genomic side and on the genomic side we're not making up any data we're not creating any information what we're doing is that we're gathering the right information for the patients um we just look at the clinical evidence we look at the clinical significance level of evidence and of course you can imagine that some gene variants uh have impacts that are more or less well known so we know it works because we're not making any information we're providing the right information to the clinician and then that's at the end the clinician that makes the decision but at least with having all the information that is uh that is uh related to um to the patient next question please um are you doing um scoring of potential illnesses that you could have and then the associated question is what are the fda polls you have and you still don't have two questions together so we we have internally a score that we decided not to display at the moment because we need small data to make sure that it's accurate what we do is that we score the clinical significance based on the data we gather we score on the um the level of evidence also if it's if the sergeant variants that have been for which papers have been published or by a large renowned institutes and confirmed by other research papers of course you can imagine that the score gets higher so this is really the way we do it we don't display our internal score the predictive score at the moment because we want to make some more trials but we provide information of the clinical significance the level of uh evidence and we if these are acmg 73 genes if those are uh curated genes so depending on the level of creation we classify and rank them different ways so what we provide to genetic counselor are basically actionable significant so five five to ten actionable to significant most important risk and then that's the decision uh that's the decision of the clinician based on other data that we might not have to to discuss it with the patient if i am a patient from european union and as we understand you're based in usa right um how my information travels um what kind of consulting services like what kind of advice medical advice i can get in the process in the process of you know receiving a digital twin and then later then my digital twin exists and it uh reacts to new uh information right so new findings new scientific findings and there is new information how does this reach me how does the communication work on my personal uh data yeah so this are two uh two great questions the first question regarding uh local regulations in europe but also we have some activities in asia so today at the moment uh all genetic counseling sessions are done from licensed genetic counsellors in the us so wherever you're in asia or europe it would be like um american i mean genetic cancer is licensed in the us that we cover it we're currently working with uh developing our network abroad and so we have signed a number of partnerships in asia uh we're in discussions also in some countries in europe to provide local uh genetic counseling uh that might come i would say in europe most probably next year in asia we already have uh have a number of them in india in thailand in singapore and other countries for the second part of your question about how we notify you of the new findings just basically uh by email or text messages saying okay you have predictive is an app so you can connect that's a web app you can connect on the website and look at your findings so when there are some new things that are um important that we consider important then in those cases we notify you by email text messages and uh early next year on the mobile app so this is the way we will notify you uh yeah and for global transportation of the sample uh does it uh i mean how long can you travel can you travel from anywhere in the world to the same address uh yes because they saw uh these are not wet samples those are dry samples uh wet samples are very you know like blood it's very complicated in terms of transportation because those are dry samples in most countries i'm not saying all countries uh because every country has its own regulation but in most countries you can just send nails or hair without having sorry thank you you can you can send nails or hair or all that kind of dry samples are usually not a problem in most countries thank you so much for your answers time's up uh so we will ask uh the jury to cast your votes on uh voting platform that was uh alex uh rashoggot from predictive and now we are going to our third pitch of the day of our uh super finals uh andreas tesla from apocula winner in the deep tech and ai category uh andreas i hope you can hear us i can hear you oh hello so now over to you and you will have five minutes and then after five minutes uh five minutes for q a from jury perfect okay my name is andreas fessler and i'm the manager of strategic initiatives here at apocular and i'm going to show you what the future of medicine is going to look like surgeons across all medical disciplines face the same problems namely you can't plan for what you can't see and you have limited support in the or in the developed world one in 20 surgeries results in an adverse event and 50 of those are caused by human error and thus considered preventable human error takes the form of poor planning poor execution poor communication or poor teamwork in the u.s alone there are 400 000 preventable adverse events annually each adverse event costs the hospital system twenty thousand dollars which equates to a total economic burden to the hospital systems in the us of eight billion dollars so if you're looking at the picture on the bottom left this is what a visceral surgeon typically sees in a liver resectioning and their task is to avoid the hepatic vein while removing half the liver with limited visibility in the middle this is what a neurosurgeon typically looks at for a hydrocephalus shunt surgery and on the right this is what a surgeon typically deals with when requesting support from a specialist and his task or her task is not to lose line of sight or train of thought so what if you could bridge these knowledge and visual gaps during surgery using cutting edge medical mixed reality like gaining depth perception with x-ray vision or planning your procedure in 3d before you make an incision or even virtually scrubbing into the surgical theater as a 3d avatar standing right next to the surgeon feeling as though you're in the room with them and that's what we're doing the world is entering into the next wave of technological interaction the first was cue uh computers with typing the second was smartphones with tapping and now with the mixed reality head mounted devices you're now able to interact with digital objects just with their hands alone and so the mixed reality is just one sub segment of the greater extended or xr world you have virtual reality that shuts out the entire real world and you're immersed in a digital environment augmented reality that superimposes one digital content over the real world and we operate in mixed reality enabling the user to completely interact with the digital objects in front of them in 3d volumetric space and so what's the important takeaway really is you know we're no longer bound to physical objects in a physical world we're now able to leverage digital objects on top of the real world for equal or greater utility and usually at a fraction of the cost was simply a software upgrade mixed reality in healthcare truly is the next market creating disruptive innovation and the key takeaways this didn't exist five years ago or really let alone three years ago um the extended reality greater market is growing at about 36 keger until 2027 and the mixed reality healthcare subsec subsegment is growing at 50 percent and so the drivers of this is finally this technology the head mounted devices are reaching a point for mass adoption and the digital health venture community is um doubling their investment spend into this space since coven 19. and i'd like to introduce the vsi whole medicine platform when looking at medical mixed reality it's broken out by the back end hardware enablers and we are partnered and leverage the microsoft hololens 2 hardware as well as the azure cloud and we occupy the front-end software layer providing surgical planning medical collaboration patient education and medical education we're medically certified ce class 1 hsa class a approved in singapore r d class 2 in canada completed our stage 1 over md sap and we're fda 510 k pending we're in 35 hospitals globally three medical schools three med device partners on boarded and across 10 different countries we're also the gold mixed rally partner of microsoft having said that we offer a subscription as a service apocalypse management team is built up as subject matter experts in molecular cell biology and polymer science as well as experienced founders and seasoned entrepreneurs we have 34 team members globally across the us germany poland and singapore additionally we have a very strong medical advisory board of 30 specialized physicians across the globe that's guiding our clinical validation and direction this spans 13 different medical fields and 10 different countries globally we're 100 bootstrap company and we're currently raising a series a round for international expansion and finally our company purpose is to become the foundational software platform and collaboration network for mixed reality-based medicine thank you many thanks to andreas jury i hope you're ready for your questions i guess i i'll kick it off um as a surgeon myself thank you for for innovating in this space i applaud what you're doing um does the technology integrate into laparoscopic and robotic surgery as well um and then a second question is what imaging modalities are you integrating into the system is it ct is it x-rays it mri is it all of them um yeah thanks yeah it's a great question so we're completely agnostic when it comes to the data sources so we were able to transform all dicom images that's ct mris angio ct's you name it from 2d you know layer by layer into a 3d volumetric object as for laparoscopic surgery or other kind of scoping devices or even ultrasounds we've developed a proprietary streamer box that enables you to simply hook in your equipment or your your scope and stream it wirelessly into the hololens right in front of you so that removes the the the burden for the physician to constantly twist their head or look around you're able to position a virtual monitor essentially directly on your field of vision over the patient and that's what we're working on as well so ideally i would be able to remove the the three four different monitors that i have around the patient and each assistant would be able to have their own device to see a laparoscopic surgery exactly yeah so the next step for the surgical theater right this technology is able to completely eliminate all physical monitors if you will and replace that with virtual monitors of any imaging any screen any live video stream that you'd like to show or even calling in another specialist either through 2d calling or as a 3d avatar standing next to you thanks yeah i see more raised hands so please go ahead with your questions i was i'm just coming out i was at all the hay hospitals when i was leading pediatric hospitals and they are using hormones massively in their surgery and also in their education so really interesting to see this um in terms of your use of ai and you use the sort of algorithms on top to to enhance this experience i wasn't quite clear how do you establish doing that is it something like you can see you know almost someone performing surgery and getting sort of uh machine learning based support in terms of the operation or is it just mainly from an education point of view yeah so there are a few sides to that so one um we have created multiple neural networks to allow the surgeon or the user to essentially filter or segment out the dicom object so think of having nerve segmentation by pressing a button and you're able to see the critical nerve structure say if you're you know an oral maxillofacial surgeon you're able to then uh segment out the trigeminal nerve or vessels um so that's one area of this and then um the other layer is uh for placement so it's automatic placement of dicom images and this is in research phase currently but you're enabling the user or the surgeon to superimpose these 3d scans of that patient onto the patient um autonomously again for research purposes currently but that's really that next step in in surgical planning more questions yeah can you speak to i mean it looks very intuitive first and foremost so that's always a good thing but i'm curious if you could speak to is there an onboarding process that does have to take place with individual surgeons and also for the let's say the surgical setup are there any adjustments that hospitals need to make when they want to implement this type of approach also a great question we're very asset light so we take up no footprint in the or whatsoever all you need is a head mounted device on someone's head physically and you're able to just augment whatever it is that you'd like to see in front of you so it actually does not require any additional hardware monitors or equipment it's an all-in-one package okay it's my time hey it's a great great presentation uh what about the competition how would you describe the competitive landscape in u.s and maybe not if you expand to europe yeah so you're seeing a lot of different competitors pop up left and right and i'd like to to keep it broad because we actually see a lot of competitors being potential collaborators with our platform um but ultimately we're competing against all players that are in virtual reality um mixed reality because um this this extended reality world it's all going to to blend together um and we see mixed reality just providing more value to the actual user in clinical practice because you're you're not limited to just one virtual world with the design burden on top of that um so that's kind of where we see ourselves currently maybe one more quick question just 20 seconds left no more questions all right thank you so much andreas uh thank you so much we ask our jury to cast their votes on the voting platform i would like to remember that we listened to andreas fassler from aprila and we already halfway through and let's move forward uh now we're trying to reach uh steve who from uh cyber health winner in the m health category so steve hello hello i hope you're ready just quick reminder five minutes for your presentation and then five minutes for the questions and answers sounds good sounds good you're ready yup let's go thank you thank you very much my name is steve zu i'm ceo co-founder of cybel health i'm a physician engineer very excited to talk about today our technology and our company so problem that we're trying to solve is foundational in in in medical care it's medical monitoring it's a 20 billion dollar market but if you look at the image on the left that's from the 1980s in a neonatal icu and you look at the image the right that's from 2020 hasn't really changed much still adhesives and wires and systems coupled to big boxes attached to the wall the major innovation has really been the outfits for the nurses so we're trying to revolutionize that at sybil and we have produced developed commercialized uh the world's first icu grade wearable sensor network it's fda cleared very proud to have that clearance essentially what it is is two devices sensors soft flexible in nature i'm actually wearing one right now that is able to capture both ecg heart sounds temperature but also blood oxygenation and together they actually give you a correlate of blood pressure in a continuous way so no more of those annoying cuffs and these devices can operate both within the hospital as well as the home so i want to share the fact that these devices also work with your smartphone you can download our app whether you're an android user or an iphone user and be able to monitor in real time with icu grade quality all the core vital signs of interest and importance whether you're in the hospital or in the home now what we've also done is gone on and developed this impressive cloud database so health data as a service it's hipaa compliant it's gdpr compliant we've actually even deployed this system uh in low resource settings with um you know philanthropies such as gates foundation and save the children foundation so it's truly a worldwide international health network linking all the sensor data that we produce onto a dashboard that's available anywhere whether you're monitoring an individual to a hospital all the way even to a population level we can do that with the anti-hub connected to our sensors our business model is one in which there is a profit margin with the hardware itself greater than 80 contribution margin so we actually make a margin on the hardware the second aspect is the accessories you know the adhesive the limb sensor that generates a usage margin so as people use the system more it generates more margin and then finally with the cloud and the analytics that we do predicting for things like decompensation or hospital emission risk we're able to charge an analytics margin so the device represents both a hardware product but then a service component behind it really allowing us to maximize revenue and sales but before that you know in the hospital we also believe there's a huge opportunity in remote patient monitoring which is really accelerated under the context of covid19 so deploying these sensors clinical grade fda cleared in the home but is as usable as a traditional wearable would be but all clinical grade you have your own phone that you can use download our app link that and that sensor data can then be used to both trigger alerts to your provider as well as the patient itself and obviously this is really useful in the context of clinical trials we're very proud to have many pharmaceutical companies many of which are our judges here today in this conference as clients and customers of cyber overall we see what we're developing here at sciabl as a platform technology these icu grade sensors that are as usable and wearable as a smart watch but clinical grade data fda cleared allows us to touch so many different areas of health care from remote patient monitoring to in-hospital care to research and clinical trials and to even sleep monitoring at a clinical level all linked to a data as a service cloud that is internationally operational whether that's in the u.s in sub-saharan africa or europe and asia all of our work is peer-reviewed so unlike a lot of other companies we publish at the highest levels our technology our capabilities in nature and science and nature medicine our data our clinical trials the how our sensors work it's all out there in the public domain after of course we patent it but that really shares and shows the kind of advanced technology we're bringing to the table which is going to change healthcare worldwide we're very proud of our joint development agreements and our partnerships enabling us to launch in more than 20 countries we have 32 active programs we'll likely touch 10 000 lives by the end of this year and partnerships with pharmaceutical clients major payers and insurance companies medical technology companies and philanthropies our strength is in our partnerships as well we've got a world-class executive team i'm a physician and engineer more than 10 years experience developing breakthrough medical devices john rogers is considered the father of flexible electronics a world-class well-respected acumen addition and engineer and a very well-rounded clinical team we have a proven financially sound engagements fda clearance and a talented committed team love to take any questions thank you steve i hope our jury yeah i see one raised hand so please go ahead uh great presentation so interesting combination obviously with the hardware and software great pro results i'm wondering about the competition obviously it's heavily uh one regulated but also there are a lot of competitors even apples and likes what is the key differentiation here so right now i'm obviously wearing a smartwatch and you know integrated into my health app and then there are all these integrations in place so what really differentiates you from them or is there partnership opportunities there um so there's both so the first and most important is technology innovation so our group our team was actually the founding group in flexible electronics so these devices i'm going to take one off are flexible bendable stretchable so they become invisible to wear most of us don't like to go to sleep wearing a watch and so i think this form factor innovation coupled to the most amount of parameters measured at all clinical grade capability is really what distinguishes us from the hundreds if not thousands of smart watch options that you have so it's really the ability to take that technology from the icu and make it as usable as a smart watch but achieve both comprehensive monitoring and far better clinical grade measurement and more of those that really distinguishes us from others with that being said we are a very open access platform our software is built on a software development kit we've integrated traditional weight scales and blood pressure cuffs and other wearables including smart watches into our software stack because we believe foundationally that more better medical data whichever device you prefer is going to be better for your health we think the annie system is the end-all physiological platform that really does the most amount of things at that clinical grade level than ever been done before and that's been shown by our leading technology and peer-reviewed papers more questions um yeah i have a question so first of all again great presentation right um but but like one of the panelists said there's huge amount of competition and it's it's going to be fairly easy for others to catch up so how do you plan to prevail well um i think that ultimately this is not a one size fits all a winner take all kind of you know process because medical monitoring is so broad and evolved but i think that ultimately where we believe we're going to win is the ability to generate tremendous amounts of clinical grade data all of it sort of stored and copied in our anti-hub that will deliver better and better insight so we're already working on you know next generation algorithms for sepsis prediction heart failure readmission risk and the fact that our devices capture the most amount of vital signs in a clinical great way kind of allows us to then develop those advanced analytics sure you can make a competing device a competing patch um i don't think it's easy to be honest but you know i think ultimately that is something where you're pointing out can be done but then our leadership in growing the number of countries a scale we've already been able to achieve with our partners will really allow us to develop deeper insights and that'll be much more difficult i'll give you a specific example we've done more than four thousand pregnant women in more than four countries across five clinical sites and we're using that data to predict for bad outcomes in maternity and that's just one example those kind of data sets and algorithms those are very hard to recapitulate and that's something that cybel is very focused on and has a leadership position in okay great i will have a question um let's look for your dream story about about do you see any risks and what how do you mitigate those risks completing this complicated platform and system having the data ai sensors all these things connected together well i think absolutely there are like a big risk that we always think about is more around cyber security and patient privacy i mean that's a big risk that as you handle a lot of patient data that you have to be up front about so i think that you know for us we built this system not only to be the most comprehensive and clinical grade but also the most secure so everything that we do is encrypted we have wireless wipe capabilities in case a smartphone or tablet is stolen or lost we follow the best practices that the fda has on cyber security protection so obviously things like gdpr compliance as well for privacy concerns so i think that when you handle something as important and precious as patient data and so much of it um that's the biggest risk that i think that we see and we're trying to be as proactive as we possibly can to ensure that that data safe secure and private by following best practices but by also innovating on things like encryption so i'll give you a specific example one of the things that we do in our device is that we actually compress and secure the device on the sensor itself and it's kind of a unique data management protocol that allows that data to be extra secure and that's things that we're doing looking ahead right where losing data or having that problem occur that's going to be a big risk and a big problem we're trying to be as proactive as possible in preventing that thank you steve zulu from uh cyber health uh time's up and we will ask uh the jury again to cast their votes on the voting platform and now we're going to the fifth pitch of the day uh eggbert schillings from life and uh winner in the hospital workflow category so egbert hello hello just a quick reminder again five minutes for your presentation and then uh questions and answers also five minutes thank you very much thanks for this opportunity to speak uh on behalf of leaf platform again it is um something that's made a lot easier by the knowledge that we are building something that all of us want to see in the healthcare systems that we work in um one of the beautiful things about being in healthcare is that if we're successful we're all going to be our own customers at some point and whether you're a venture capitalist an engineer a doctor a business builder we all want to see healthcare systems that are a bit more like this person-centered now we've talked about this for an awful long time but in the age of digital i think we're finally at a point where we know that we can deploy tools and information to the people who need them when they need them they can be deployed to us as patients so we can be more self-empowered and most of all they can be deployed to those who take care of us when we need it the most to do this though one has to connect all of the dots and leafin as a company was founded to do just that and we realized some of those dots are actually documents healthcare creates millions and millions of documents every single day and they need to go from one stakeholder to the other they need to go from the lab to the doctor to the hospital to the patient and they don't always do this with the precision and the speed that we want them to they get lost they don't end up in the ehr and that's why the big leaf and brain was created essentially a platform that is plugged into the ehr or the practice management system it can read the documents sends them to the platform where the algorithms read those and then sends on the information that needs to be sent on to those who need to have them that's connecting the dots and we realize that what you see on the right hand side here is ultimately the future of all of digital healthcare it's about data data needs to flow it needs to be connected identities need to be managed and things need to be distributed and now we're at a level where close to 600 hospitals trust us to do just that tens of thousands of professionals and millions of documents and they are exchanging those through these nodes here every single thing is essentially an instance of somebody using this platform to distribute medical data to others who need to have it when i first saw it i thought immediately of a brain where all the neurons are firing and that is essentially what we've built now the time has come to take all of the great innovation that sits in the cloud and to deploy that all along the patient pathway there's tremendous innovation going on all of you probably open your emails every morning and go to your aggregated websites and you can see the fantastic stuff happening in every vertical in every functional and clinical one dozens and dozens of new products and services and companies but for all of this great new innovation to be deployed in a way that it inflects outcomes that it actually enhances the patient experience or reduce cost they have to be connected in a meaningful way all of those dots so i want to show you in one use case example on how we are foundational to doing just that many of you will have heard of apiace bay which is a giant hospital system in paris 6 million patients 33 campuses and like everyone i'm speaking to now they realize the future of health is digital so they created a project called the at hotel you where they invited a number of very innovative companies to create something that is necessary for patient-centered care and that is a more integrated pathway so you have them invite companies like nabla where you can use chatbots to get information on health conditions where that data then can flow into the pathway even before the first healthcare professional has touched the patient all the way to the other end of the pathway after diagnosis or surgery where then fabulous company like withings which was discussed a lot at the conference can use very ambient very elegant devices to do remote monitoring but all of it comes together only because of the leafing platform because we were invited to make sure that these systems get integrated because we know that when you enroll a patient in a new tool let's say an oncology self-management tool you don't want to do this by hand you want this to be elegant we know how to pull the data from the patient administration system and populate all the right fields we create single sign-on so clinicians can go between different applications without having to sign in and sign out which enhances the workflow and makes things more efficient and of course the organizations want to monitor all of this activity for which we provide a dashboard where you can look at authorization do audits establish business rules this is the sort of thing we've built with the platform and that is why we have a lot of companies now joining us great entrepreneurs creating new technology to be plugged into those neuronal networks we're at a stage in our company journey that is very exciting we're looking back on five years where many people have trusted us with their documents with their data and also with their money as investors and we hope that tonight all 140 of us will get you a vote of confidence as well thank you very much thank you very much indeed and uh now it is time for the jury questions go would like to start yes can you speak a little bit to your um your geographic expansion plans um it wasn't quite clear to me maybe i missed it where your um scope is at the moment and where you're heading next yes we're very proud that this big brain of neurons sits in france that's where we're headquartered so now our desire is to inkblot our way across the continent and hopefully also across the english channel um weather permitting so yeah we are seeking to enter new markets and we're working on our first uh proofs of concept and we hope to have good news before the end of the year but uh we will be focused on uh on europe for now more questions we've still got four minutes more than four minutes like if i can do a follow-up question who do you consider to be your primary purchaser on the customer side so our natural home is with the providers because uh you saw 577 hospitals who decided to join us on this journey so traditionally who we're talking to are the cios who are seeking to bring all the great new innovation from the cloud and integrate it into their primary data systems and in order to for that to be a successful project that scales and that you can do at speed that's who we generally speak to having said that though there are many others building digital ecosystems who will benefit from interoperability between different systems especially cloud native systems with on-premise systems so we're also speaking with insurance companies with medical device companies obviously and also research and development our home is in the provider space and that's still our natural audience but we're segmenting out to others as well i see more raised hands go ahead please all right uh i'd like to ask you about the competition there are big players also in this this have ig sector and so how would you describe your your competitors absolutely they're established companies that do nothing but integration projects and uh that work on them very successfully and very profitably the way we differentiate ourselves from them is that we want to get away from the point-to-point integration that is always a project that always takes several months and to reuse connectors and those apis in those primary data systems so that once you have those in place you're in a good position to then bring in the next innovation and that doesn't have to be another big project it's actually more point-and-click and as people join the platform the deployment on the provider side becomes that much easier so the way we would differentiate ourselves is to say we want to make sure that this scales and we want to do this at much lower cost than maybe some of the incumbent players more questions please yeah now i'm just going to comment the interferability challenge here in here in england is a big one and we have lots of programs we have lots of systems and we also have uh you know we're trying to integrate our care between primary and secondary care so you've talked about hospital workflows but actually there's a big impact on on integrated care systems and how we sort of increased the act upon that have you given that any thought no kind of what would you you mentioned you know you want to come over this side today in the channel so what have you before about how you how you approach that yeah no question there's tremendous work being done in the nhs to ultimately create integrated care systems and they will always involve people that are doing social care in completely different settings in the hospital and also in the practice management of the individual gps and many points beyond we've already integrated ourselves with practice management systems of gp so we know how that works and we think that ultimately the same principle can always apply that once the connector is in place you need to just standardize the data flow you need to probably clean it up and need to raise the visibility on what's going on so that it can be done safely so i am always guided by my original work experience which was at kaiser permanente in california where i could see that having a horizontally and vertically integrated system where the patient is really at the center of it and the data flows to every stakeholder within it is the way to go now not every system can be like that but i think there are those and i've seen definitely among the csus and the ccgs enormous steps in that direction we will be delighted to be part of that solution because it's absolutely true this is not about the hospital the future healthcare system as we looked at in the first slide is about the individual not about a building and we think we can be the pipes to make that data flow mr model your quick question sure so um thanks and good to see you again um good story so far but what's next new product new services new business models what's next next is more apps to join us on the platform so all kinds of individual companies that want to go fast more connectors into data systems so that we can guarantee more data streams that are interoperable and more experience working with those ehr systems that are so crucial because they're the single source of truth that would be next for us and doing all of that in more markets than in france many thanks to albert schillings from leafan he is the winner in the hospital workflow category and again we ask our jury to cast your votes on voting platform and now we're moving to the last pitch of the day uh uh miller montgomery from uh micronoma uh the winner in the diagnostics uh category uh uh still i just receiving the information from our technical group that uh they are trying to reach her the last but not least the sixth pitch uh today and then uh yeah i think we have uh sandrines sandrine hello hello oh yeah absolutely perfectly we hear you and how does it feel to be you know uh the last but not least because this is the last pitch of the day i feel very special and honored and i hope it's not too late for you because it's very early still for me okay so coffee time yeah it's evening already dark outside but yeah we you know broadcasting to all over the globe so somewhere it's night somewhere it's morning somewhere it's uh just afternoon so i hope you're ready five minutes for you for presentation and then five minutes four questions okay perfect i'm looking forward to that hi everyone so good morning good afternoon good evening uh i'm samurai milan montgomery i'm the ceo of micronoma we have been awarded the the winning position for the category of diagnostic and right now i'm going to explain to you what we're diagnosing so we do diagnostic of early cancer early stage and we're using liquid biopsy with a with a twist we are using microbiome driven liquid biopsy so first why are we focusing so much on early cancer detection well it's because each year as we know cancer kills a lot of people but four million of these tests could be prevented if only there was an early detection methodology there is a lot of people who are looking in the field of liquid biopsy for the right biomarker but we think that they are focusing on the wrong biomarkers for early cancer addiction mentally more a little bit more later and additionally we want to find the cancer at the right time not too early and not with sparse positive because we don't want to create false care in the patient so here's the leadership team we are a mixture of computer scientists ai expert as well as oncologists and microbiome people all coming together to be able to create this solution uh i mentioned we are using microbiome driven liquid biopsy why are we doing that and what is microbiome so first microbiome is the communities the many communities of microbes that are living in us and within us there are bacteria virus and fungi now when we look at the number of genes uh the number of human genes that we can query for biomarkers are only 23 000 microbial genes on the other and there is a huge diversity of more than 2 million and that's likely coming from the fact that microbes were on the planet way way before humans were and they had time to evolve and diversified way more and so we are mining this diversity to find biomarkers of of cancer people are looking in microbiome in uh in oral microbiome skin or gut microbiome because they are easily accessible like the outside of this donut but the problem with this microbiome is that they are very valuable with your dental hygiene your skin lotions or your diet so the team has been very focused on looking at what is the dough of this donut which is either the tissue or the blood compartment because they are naturally protected and mostly homeostatic our first council of interest is lung cancer uh it's it's unfortunately a very prevalent cancer and a very deadly one the survival rate at five years is less than 20 percent uh despite the fact that there is a very nicely established state of the art the problem with uh the state of the art is that the first step is to go through low-dose ct scan not not expensive uh minimally invasive but when you find a nodule in the lung you have to go to tissue biopsy to no more and that's a problem because it's expensive and it's risky and thankfully only five percent of the modulars are going to be malignant but that means that 95 of the time you go through this risk and this expense for no reason so that's where we are going to go first uh with our micro normal solution it's like a liquid stick a liquid biopsy platform you start with very little amount of blood you sequence it you look at the microbes and you figure out uh if someone has my cancer or not our data has been published in the journal nature uh in 2020 where we query uh more than eleven thousand patient samples to arrive to multiple uh conclusion the most important one for micronomial which was can we predict a cancer from just looking at the microbial signature we can find in the blood and the answer was yes here are some of the data showing you that performance are similar when we look in the tissue or in the blood uh we reproduce these results on a smaller cohort looking at plasma which was way more practical for our need and same thing again we recapitulated the result as you can see in our nature article very great sensitivity for very great specificity so with that micronumber has been launched uh we are doing a larger cohort study on about in fact more than a thousand cancer samples and controls and we're looking at the spectrum from healthy control to benign as well as cancer patients so that we can answer this question do you have malignant cancer or is it benign we are focusing on lung right now but we have a long pipeline ahead of us and we are right now in a series a uh raising 30 million that should close later this year i thank you very much for attention and welcome your questions thank you so much sirdrin and uh it is time for the questions now do you remember us who would like to start oh i see the raised hand please go ahead yes thank you very very good presentation and very inspiring and very important area that you are now tapping into and my question is that uh who are your clients and and what's your revenue model yes so our clients are going to be the oncologists and the pulmonologists for lung cancer obviously uh the the specialists are going to depend on the cancer we are looking at but they are going at first to be radiologists permanent oncologists who are going to want to have an alternative to tissue biopsy to evaluate their their patient we are going to be receiving samples from this patient here in our headquarters in california that we are going to process and analyze on on site under a clear cap regulation much like other liquid biopsy uh offering here our main uh differences here is going to be that we are looking at microbiome signature instead of signature coming from the cancer directly um what is the financial model uh behind it how does the actual earning of the money works and what is the potential and sort of profitability of such a venture well what's working in our advantage for liquid biopsy is that we are new using negation sequencing which the cost is going to is getting lower as we speak as well as ai and computing cost is going lower as as well so um that's the cost itself is going lower in our business favor meanwhile the need is still high and so there is uh for for a minimally invasive uh methodology and so there is a clear need to have a solution that's going to be cost effective for the uh for the care system and the patient but still uh leaving a lot of margin for micronoma to be able to operate while developing uh our pipeline uh the the way we are positioning ourselves is very likely to have an acquisition in our in our future so most of the money we are raising is not leading toward commercialization because likely an acquirer would have all of their marketing and commercial channel already well established so not to say we don't want to have a sales team or marketing team we will have it but in a reasonable scope so that most of our funding and revenues are geared toward growing our pipeline what are some of the limitations of this diagnostic approach relative to the biopsy methods and other established diagnostic processes so liquid biopsy other methods in liquid biopsy are there a limitation that we do not have so let's talk on the positive side first we don't have the limitation that the marker we are looking at are not linked to the side size of the tumor so most of the liquid biopsy technology are looking at mutation methylation pattern and all of this signal is coming from the tumor if you have a large tumor you're going to have a lot of signal in the blood if you have a small tumor which is the case in early stage you won't have as much signal our signatures are not coming from the tumor exclusively it's coming from the tumor the environment the host response so that's increasing our power of detection sensitivity and specificity in the early stage our limitation is going to be for some cancer we cannot do what tissue biopsy can do which is staging telling you if your stage one two three or four and that is because in some cases the tumor microbiome itself for some cancer type is not going to change from stage one to a stage four on the other hand some cancer as we have shown in the nature paper their microbiome is going to evolve from from stage 1 to stage 4. so that's a limitation where for tissue biopsy you're pretty much always able to stage the cancer in our cases we will not be able to stage in all cancer type tropon the last question for you yeah um so you mentioned that in terms of you don't really have a plans for commercialization but want to be acquired if you will um so what is your current revenue and your financial situation so so let me rephrase that it's not that we do not have a plan for commercialization we have a plan for targeted and lean commercialization so we are going to absolutely do and commercialize or else no one will know about it and no one will uh and we won't have a revenue generation we are just doing a very targeted approach for key centers when we are going to make a major difference uh and key uh paying or pay your organization that are going to recommend our methodology because it's going to generate a very significant cost saving for them that is how we are going to be able to generate our revenue it's through a very targeted approach of our cell channels cedrine montgomery from micronoma thank you so much and uh again we ask our jury members to cast their votes on the voting platform and uh this is it uh we're ending super finals and the last uh time uh today we announced a short break it's gonna be up to 15 minutes and after 15 minutes we will know who is the winner [Music] ladies and gentlemen welcome back uh to the momentum of uh our uh last conference day soon we will know who is the winner from uh healthtech challenges and i am sure that you are just about excited to know who it is so without any further ado let me invite uh mr eman tasmikshi cpo of our event host killer health for the big reveal and of course closing remarks so hey mantas welcome how are you today what a day what an exciting day actually uh a lot of difficulties but nevertheless we finally have a video yeah finally we have the winner and uh probably it is uh good time to announce what is the prize for the winner of course and uh the winner will receive an equity free money prize which is 10 000 us dollars sounds great yeah that's a lot of money actually absolutely and of course there will be uh some more additional uh prices for the category winners for the challenges and of course the winner also will receive some really really nice prizes as well uh and of course equity free uh price uh which is 10 000 u.s dollars yeah so basically uh should we start or should we uh have a little bit of intrigue oh i i think we could uh we could have some uh uh some small intrigue yeah why not basically so uh ladies and gentlemen my name is amanda's makeshift as you already know and i was part of the jury uh and uh but before i had announced the winner i actually want to say that uh and share a few things from my personal experience and it doesn't matter it doesn't matter actually if you're going to win or lose today and of course it definitely helps to win such contests and participate in such consciousness uh and uh i know that some at some point it might maybe sounds a little bit strange that i'm saying things like that uh uh by being part of this amazing uh conference an amazing pitch battle but uh the real businesses actually succeed not in the pitch battles and i know that you will get like a lots of publicity uh maybe uh lots of attention from potential investors uh if you go if you're going to be a winner of this contest maybe uh you even have uh uplift your uh team spirits but uh real businesses actually succeed not in the beach battles and the real businesses succeed in wild market conditions and i know this from my uh like rough personal experience and the lessons already learned uh and i really wish that all of you actually today uh you were all great and uh the difference between the winner and the second and the third place is actually very tight uh so i'm actually really hope uh hoping that you all succeed in those wild market conditions uh and uh you'll do great so uh first of all like thank you all uh for participating in the the pitch battle and uh i'm sure that we can announce uh the winner without all the forever further ado and uh drums ladies and gentlemen uh the ultimate winner of health tech challengers 2021 is cognitive fit uh and uh i'm told that we might have carlos uh one of the co-founders of the company so we can actually congratulate him and ask him a few questions hello carlos hello thank you congratulations thank you thank you it was an incredible surprise so interesting day thank you for organizing all this so basically you uh you already created like amazing company and uh your product sounds really interesting how do you feel about the win today i feel great that's kind of fantastic and somehow inspected because i kind of participate on all this by luck because i received an email from you and i was so handsome emails that i kind of decided to to join the context and and see uh and present it like by luck and then now we are the winner so it's like a huge thing so thank you very much thank you very much for for trusting for understanding for the support to our project yeah congratulations one more time and uh i want to ask you uh last question uh and uh i guess you'll go to you you'll have enough time to celebrate today uh what are your next plans for what are the next big things for your company yeah the next big things basically is like we are now in the in the process of rolling out the technology that we have been developing through the years uh so now in the in the process of fundraising a significant amount of money in order to deploy all the technology and commercialize digital therapeutics technology in the u.s and in europe so so it's a big jump moving into from wellness to digital pharma so i think it's the right moment in time for society for the company uh uh and for the world to to to leverage and use our technology so that's what is happening now i wish you all the best collage and uh good luck with your fundraising and uh good luck with your company thank you thank you congratulations one more time thank you and i guess by wrapping the conference up i also like to sum up a few things and few thoughts uh from the previous days uh we had more than 100 speakers from different countries different companies uh like microsoft buyer astrozenica kill health of course uh and i would like to thank you uh for participating and taking your time uh for this amazing event uh and uh i believe that uh this conference would be uh the first step uh in uh revolutionizing uh the health care and as we all know uh the there actually will hardly be another year of uh such uh change that healthcare system uh actually uh had an experience uh as it was in 2020 uh the global pandemic actually shifted the focus and pushed the sector to adapt and innovate and it also defined how we are going to actually perceive and see the healthcare system uh in the next within the next uh 10 years and of course new technologies uh changed uh there there always were new technologies and uh they always existed in the digital health within the digital health companies but the money wasn't there and the funding in greece uh and within the last year within the 2020 uh digital health companies raised more than 20 billion united states dollars uh which is all-time high uh incredible achievement and the on-demand healthcare was one of the uh actually it was the most valued value proposition uh with in 2020 so uh this kind of means that we are on something big and this trend continues to this year and i think that health tech forward 2021 conference has taught us so much about what it means to push digital health uh boundaries and how to start a new successful health venture and furthermore achieve a better future for global health care through collaboration so thank you all for joining today and making excellent and unforgettable experience thank you all and see you next year absolutely hey thank you so much for your closing remarks and uh yeah we would like to thank everybody for participation thank uh we would like to thank all the speakers we would like to thank all the viewers and uh well well uh we would like to thank our sponsors without them uh this uh became possible and uh once again uh give it up for uh press sergeant uh easy big health uh medicta we care prabha health gig xr and yours app it was really great uh pleasure to work with you and we thank everyone and uh lots of love from the city of veldneus bye you

Channel: Futurae Media

Views: 8,476

Rating: 4.9649124 out of 5

Keywords:

Id: -DBhlGWlleA

Length: 82min 25sec (4945 seconds)

Published: Thu Oct 14 2021